TACE治疗既往有肝功能衰竭史肝癌患者七例  

TACE treatment for patients with inoperable hepatocellular carcinoma and hepatic failure history:initial experience in seven cases

作　　者：杨柏帅[1] 施裕新[1] 袁敏[1] 王介非[2] 周粟[1] 王峻峰[1] 

机构地区：[1]复旦大学附属公共卫生临床中心影像科,201508 [2]复旦大学肝病临床中心

出　　处：《介入放射学杂志》2014年第9期805-808,共4页Journal of Interventional Radiology

摘　　要：目的探讨TACE术在既往曾有肝功能衰竭的肝癌患者中应用的安全性和有效性。方法既往有肝功能衰竭病史,接受TACE术的患者7例,既往肝功能衰竭痊愈距行TACE治疗时间平均3.5年。监测其术后不良反应,生化指标变化程度,至少随访6个月,与同期接受TACE术,且无肝功能衰竭病史的51例进行对比。结果有肝功能衰竭史的患者,TACE术后随访期内无相关性死亡,未发生严重不良反应,轻度不良反应发生率与对照组无显著差异,术后短期内,与对照组相比,丙氨酸转氨酶、总胆红素、凝血酶原时间、白蛋白均有明显异常,但术后1个月,上述指标均能恢复,且术后6个月随访,两组肿瘤控制率无明显差异。结论对于既往有肝功能衰竭病史,且有无法手术切除的肝癌患者,仍可行TACE术,且是一项安全的治疗手段。Objective To discuss the safety and efficacy of transcatheter arterial chemoembolization （TACE） in treating patients with inoperable hepatocellular carcinoma （HCC） who has a history of hepatic failure. Methods A total of 7 HCC patients who had a history of hepatic failure （study group） were enrolled in this study. TACE was carried out in all these 7 patients. Other 51 patients who had no liver failure history were used as the control group. All the patients were followed up for at least six months. The postoperative adverse events, changes of liver function and the prognosis were recorded, and the results were compared between the two groups. Results In the study group, neither treatment-related death nor severe adverse events occurred. No significant difference in the occurrence of mild adverse events existed between the two groups. After TACE the liver functions, including alanine aminotransferase, total bilirubin, prolonged prothrombin time, albumin, etc. in the study group were significantly worse than those in the control group,groups. Conclusion For patients with inoperable hepatocellular carcinoma who has a history of hepatic failure, TACE is a safe and effective treatment.

关 键 词：肝细胞肝癌 肝衰竭 经导管内动脉化疗栓塞术 

分 类 号：R735.7[医药卫生—肿瘤]